The Latest Cardiac and Vascular News
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its first quarter ended March 31, 2018. Recent Highlights and Accomplishments Realized revenue of $1.5 million in the first […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into definitive agreements to issue newly-designated Series A Convertible Preferred Stock to a select group of existing investors […]
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today reported financial results for its fourth quarter and year ended December 31, 2017. Recent Highlights and Accomplishments Revenue of $4.2 million in the […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that James (Jim) Tobin has been appointed to its Board of Directors, effective immediately. President and Chief Executive Officer Mark Toland stated, “I […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (Formerly known as Corindus), Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the successful completion of the first robotic-assisted peripheral vascular intervention procedure using the recently FDA-cleared CorPath GRX System. […]
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled “Complex […]
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it is working with Mayo Clinic in a preclinical study about use of telestenting. Telestenting, or the remote robotic treatment for percutaneous coronary intervention (PCI), […]
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System outside of the United States. The system was purchased by the Apex Heart Institute […]
